Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 5, 2010, Pages 477-481

  Coria Ramirez, Erika ^a   Cisneros, Leopoldo Nieto ^a   Treviño Perez, Sandra ^a   Ibarra Gonzalez, Isabel ^b   Casillas Rodriguez, Jesus ^a   Majluf Cruz, Abraham ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

antiretroviral therapy; cardiovascular risk factors; HIV infection; hyperhomocysteinemia; thrombosis; venous thromboembolic disease

Indexed keywords

COTRIMOXAZOLE; CYANOCOBALAMIN; DIDANOSINE; EFAVIRENZ; FOLIC ACID; HOMOCYSTEINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; METHIONINE; NELFINAVIR; PYRIDOXINE; RITONAVIR PLUS SAQUINAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; VIRUS LOAD; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ERYTHROCYTES; FEMALE; FOLIC ACID; HIV INFECTIONS; HIV-1; HOMOCYSTEINE; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; VITAMIN B 12; VITAMIN B 6;

EID: 77955012573     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181d91088     Document Type: Article

References (48)

1. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-F105.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell count of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337: 734-739.
4. Rizzardi GP, De Boer RJ, Hoover S, et al. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest. 2000;105:777-782.
5. Rutschmann O, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS. 1998;12:F71-F77.
6. Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health-Syst Pharm. 2004;61:2507-2522.
7. Vittecoq D, Escaut L, Chironi G, et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS. 2003;17:S70-S76.
8. Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109:316-319.
9. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med. 1999;131:376-386.
10. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165-176.
11. Selhub J, Jacques PF, Wilson PW. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993; 270:2693-2698.
12. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
13. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
14. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50:3-32.
15. Carducci C, Birarelli M, Nola M, et al. Automated high-performance liquid chromatographic method for the determination of homocysteine in plasma samples. J Chromatogr A. 1999;846:93-100.
16. Palella F, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
17. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
18. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
19. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
20. The D.A.D. Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
21. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses of the SMART trial. Antivir Ther. 2008;13:177-187
22. d'Arminio A, Sabin CA, Phillips AN, et al. Cardio-and cerebrovascular events in HIV-infected persons. AIDS. 2004;18:1811-1817.
23. Law MG, d'Arminio A, Monforte A, et al. Cardio-and cerebrovascular events and predicted rates of myocardial infarction in the D.A.D. study. Presented at: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
24. Force L, Barrufet P, Herreras Z, et al. Deep venous thrombosis and megestrol in patients with HIV infection. AIDS. 1999;13:1425-1426.
25. Jenkins R, Peters BS, Pinching AJ. Thromboembolic disease in AIDS is associated with cytomegalovirus disease. AIDS. 1991;5:1540-1542.
26. Duerksen DR, Ahmad A, Doweiko J, et al. Risk of symptomatic central venous thrombotic complications in AIDS patients receiving home parenteral nutrition. J Parenter Enteral Nutr. 1996;20:302-305.
27. Majluf-Cruz A, Silva-Estrada M, Sánchez-Barboza R, et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb/Hemost. 2004;10:19-25.
28. Becker DM, Saunders TJ, Wispelwey B, et al. Case report: venous thromboembolism in AIDS. Am J Med Sci. 1992;303:395.
29. Stahl CP, Wideman CS, Spira TJ, et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood. 1993;81:1801.
30. Bissuel F, Berruyer M, Causse X, et al. Acquired protein S deficiency: correlation with advanced disease in HIV-1 infected patients. J Acquir Immune Defic Syndr. 1992;5:484.
31. Toulon P, Lamine M, Ledjev I, et al. Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus. Thromb Haemost. 1993;15:730-735.
32. Koppel K, Bratt G, Schulman S, et al. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:441-449.
33. Pasternak RC, Grundy SM, Levy D, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol. 1996;27:978-990.
34. Weiis N, Koelle P, Postea O, et al. Highly active antiretroviral therapy for HIV-infection increases plasma homocysteine concentrations. J Inherit Metab Dis. 2003;26(Suppl 1):89.
35. Bernasconi E, Uhr M, Magenta L, et al. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS. 2001;15:1081-1082. (Pubitemid 32476686)
36. Bongiovanni M, Casana M, Pisacreta M, et al. Predictive factors of hyperhomocysteinemia in HIV-positive patients. J Acquir Immune Defic Syndr. 2006;44:117-119.
37. Uccelli MC, Tordi C, Lapadula G, et al. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. Ann Nutr Metab. 2006;50:247-252.
38. Raiszadeh F, Hoover DR, Lee I, et al. Plasma homocysteine is not associated with HIV serostatus or antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2009;51:175-178.
39. Herbert V. Experimental nutritional folate deficiency in man. Trans Assoc Am Physicians. 1962;75:307-320.
40. Hoffbrand AV, Newcombe BFA, Mollin DL. Method of assay of red cell folate activity and the value of the assay as a test for folate deficiency. J Clin Pathol. 1966;19:17-28.
41. McCully KS. Homocysteine, folate, vitamine B6 and cardiovascular disease. JAMA. 1998;279:392-393.
42. Garrow TA. Purification, kinetic properties and cDNA cloning of mammalian betaine-homocysteine methyltransferase. J Biol Chem. 1984; 271:22831-22838.
43. Van der Griend R, Hass FJ, Duran M. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med. 1998;132:67-72.
44. Minniti G, Cerone, R, Caso M, et al. Role of methionine load in detection of mild hyperomocysteinemia. J Inherit Metab Dis. 2003;26(Suppl 1):52.
45. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
46. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
47. Olthof MR, van Vliet T, Boelsma E, et al. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003;133:4135-4138.
48. Olthof MR, Brink EJ, Katan MB, et al. Choline supplemented as phosphatidylcholine decreases fasting and postmethionineloading plasma homocysteine concentrations in healthy men. Am J Clin Nutr. 2005;82: 111-117.